ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2921

Contraceptive Factors Are Associated with Serum Antibodies to Citrullinated Protein Antigens in Women at Elevated Risk for Future Rheumatoid Arthritis

Sonia Khatter1, Mark C. Parish2, Marie L. Feser2, Jason R. Kolfenbach2, Ryan W. Gan3, Michael H. Weisman4, James R. O'Dell5, Ted R. Mikuls6, Richard M. Keating7, Peter K. Gregersen8, Jane H. Buckner9, V. Michael Holers10, Kevin D. Deane2, Jill M. Norris3 and M. Kristen Demoruelle2, 1University of Colorado School of Medicine, Aurora, CO, 2Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, 3Epidemiology, Colorado School of Public Health, Aurora, CO, 4Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, 5Veteran Affairs Nebraska Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE, 6Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, 7Division of Rheumatology, Scripps Clinic, La Jolla, CA, 8Genomics and Human Genetics, Feinstein Institute for Medical Research, Manhasset, NY, 9Benaroya Research Institute at Virginia Mason, Seattle, WA, 10Rheumatology Division, University of Colorado School of Medicine, Aurora, CO

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: anti-CCP antibodies, rheumatoid arthritis (RA) and women's health

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Human Etiology and Pathogenesis II: Citrullination, Autoantibodies and Genes

Session Type: Abstract Submissions (ACR)

Background/Purpose: The preclinical period of rheumatoid arthritis (RA) development is characterized by elevations of serum RA-related autoantibodies (Abs) including Abs to citrullinated protein antigens (ACPA) and rheumatoid factor (RF). Serum ACPAs are highly predictive of future inflammatory arthritis (IA) classifiable as RA, and recent data suggesting that ACPAs are directly pathogenic in joint disease highlight the need to understand the etiology of ACPA development. In addition, it remains unknown why RA disproportionately impacts women compared to men, and data suggest hormonal factors may influence the risk of developing RA. Importantly, prior data from our group identified that oral contraceptive pill (OCP) use was associated with a decreased risk for serum RF positivity in the absence of IA (Bhatia 2007). Therefore, we hypothesize that contraceptive factors will be associated with serum ACPA positivity among arthritis-free women at increased risk for RA.

Methods: In the Studies of the Etiology of RA (SERA) project, 1243 first degree relatives (FDR) of probands with RA are enrolled who are women. Of these FDRs, we studied women who at their baseline visit had serum ELISA testing for ACPA using anti-CCP3.1 (IgG/IgA, INOVA) and a detailed prior contraceptive and pregnancy history obtained using a standardized questionnaire (N=336). To avoid familial correlation, we also randomly selected only one subject per family; therefore, our final analyses included 297 FDRs.  All subjects were without clinical IA at the time of serum testing. In cross-section, associations of ACPA and subject factors were analyzed using chi-squared and logistic regression.

Results: In multivariate analyses, prior use of OCPs was associated with a decreased risk of serum ACPA positivity (OR=0.34; 95% CI 0.15-0.79; adjusted for age, race and smoking). In addition, there was an increased risk of ACPA positivity in women who had a history of intrauterine device (IUD) use (OR=2.68; 95% CI 1.11-6.47; adjusted for age, race and smoking). ACPA(+) FDRs were slightly older than ACPA(-) FDRs, but were similar in race, smoking and shared epitope status (Table). No significant association was seen between ACPA positivity and pregnancy or breastfeeding.

Conclusion: Prior OCP use was associated with a decreased risk of ACPA positivity in these FDRs, and these results are in line with our prior findings of OCP use associated with a decreased risk of RF positivity. Of interest was the association of an increased risk of ACPA positivity with IUD use. While the mechanisms that link contraceptive factors to ACPA generation are unknown, unlike OCPs, IUDs have been shown to generate endometrial inflammatory responses. Therefore, the association of IUD use and ACPA suggest that IUD-induced endometrial inflammation may be a potential mucosal trigger of RA-related Abs. Mechanisms by which OCPs could protect and IUDs could increase risk for RA-related autoimmunity need further study.

 

Table. Contraceptive and Other Risk Factors for ACPA Positivity in Women at Elevated Risk for Future RA

 

ACPA (+) (N=34)

ACPA (-) (N=263)

p-value*

Unadjusted OR (95% CI)

Adjusted OR (95% CI)**

History of OCP use (%)

64.7

84.4

<0.01

0.34 (0.16-0.74)

0.34 (0.15-0.79)

History of IUD use (%)

26.5

12.9

0.03

2.42 (1.04-5.63)

2.68 (1.11-6.47)

Age, mean (SD)

52 (17.3)

46 (15.8)

0.07

1.02 (1.0-1.05)

 

Race, white non-Hispanic (%)

73.5

77.2

0.63

1.22 (0.54-2.75)

 

History of ever smoking (%)

29.4

35.7

0.47

0.75 (0.34-1.63)

 

≥1 shared epitope allele (%)

50.0

54.3

0.64

0.84 (0.41-1.72)

 

History of pregnancy (%)

73.5

75.3

0.82

0.91 (0.40-2.05)

 

Number of pregnancies, mean (SD)

2.0 (1.7)

2.1 (1.7)

0.66

0.95 (0.77-1.18)

 

History of breastfeeding (%)

44.1

46.0

0.84

0.93 (0.45-1.90)

 

Total duration breastfeeding, mean (SD)

8.6 (21.5)

7.3 (14.3)

0.63

1.01 (0.98-1.03)

 

Age of menses onset, mean (SD)

13 (1.5)

13 (1.3)

0.85

0.98 (0.77-1.25)

 

* Calculated comparing ACPA(+) versus ACPA(-) subjects, chi-squared and t-test used as appropriate

**Odds ratios were adjusted for age, race and history of smoking

Abbreviations: ACPA=antibodies to citrullinated protein antigen, OCP=oral contraceptive pill, IUD=intrauterine device

 


Disclosure:

S. Khatter,
None;

M. C. Parish,
None;

M. L. Feser,
None;

J. R. Kolfenbach,
None;

R. W. Gan,
None;

M. H. Weisman,
None;

J. R. O’Dell,
None;

T. R. Mikuls,
None;

R. M. Keating,
None;

P. K. Gregersen,
None;

J. H. Buckner,
None;

V. M. Holers,
None;

K. D. Deane,
None;

J. M. Norris,
None;

M. K. Demoruelle,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/contraceptive-factors-are-associated-with-serum-antibodies-to-citrullinated-protein-antigens-in-women-at-elevated-risk-for-future-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology